Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Non-Current Assets for 8 consecutive years, with $11.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 44.58% year-over-year to $11.4 million, compared with a TTM value of $11.4 million through Sep 2025, down 44.58%, and an annual FY2024 reading of $17.2 million, down 37.91% over the prior year.
  • Non-Current Assets was $11.4 million for Q3 2025 at Bicycle Therapeutics, down from $14.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $37.0 million in Q1 2023 and bottomed at $5.7 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $21.6 million, with a median of $22.5 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 442.27% in 2022, then crashed 44.58% in 2025.
  • Year by year, Non-Current Assets stood at $17.8 million in 2021, then surged by 84.2% to $32.8 million in 2022, then fell by 15.52% to $27.7 million in 2023, then tumbled by 37.91% to $17.2 million in 2024, then tumbled by 33.54% to $11.4 million in 2025.
  • Business Quant data shows Non-Current Assets for BCYC at $11.4 million in Q3 2025, $14.1 million in Q2 2025, and $15.4 million in Q1 2025.